Joseph M. Miller Sells 61,859 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) CFO Joseph M. Miller sold 61,859 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $494,872.00. Following the transaction, the chief financial officer now owns 633,515 shares of the company’s stock, valued at approximately $5,068,120. This represents a 8.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Aurinia Pharmaceuticals Trading Up 1.3 %

AUPH traded up $0.10 during trading on Tuesday, reaching $8.08. 3,640,172 shares of the stock traded hands, compared to its average volume of 1,449,999. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $1.16 billion, a PE ratio of -53.86 and a beta of 1.22. The stock’s 50-day moving average is $8.13 and its 200 day moving average is $7.85. Aurinia Pharmaceuticals Inc. has a 12 month low of $4.71 and a 12 month high of $10.67.

Analyst Ratings Changes

Separately, StockNews.com downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 19th.

Institutional Trading of Aurinia Pharmaceuticals

A number of institutional investors have recently bought and sold shares of AUPH. Segall Bryant & Hamill LLC boosted its position in Aurinia Pharmaceuticals by 1.6% during the third quarter. Segall Bryant & Hamill LLC now owns 562,775 shares of the biotechnology company’s stock valued at $4,125,000 after acquiring an additional 9,031 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Aurinia Pharmaceuticals during the third quarter valued at $3,330,000. Intech Investment Management LLC bought a new position in shares of Aurinia Pharmaceuticals during the 3rd quarter worth about $262,000. Charles Schwab Investment Management Inc. boosted its position in shares of Aurinia Pharmaceuticals by 13.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 744,050 shares of the biotechnology company’s stock worth $5,454,000 after purchasing an additional 89,940 shares in the last quarter. Finally, FMR LLC boosted its position in shares of Aurinia Pharmaceuticals by 44.8% during the 3rd quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock worth $93,000 after purchasing an additional 3,919 shares in the last quarter. Institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.